Literature DB >> 32915345

The association between aortic valve calcification, cardiovascular risk factors, and cardiac size and function in a general population.

Lida Khurrami1, Jacob Eifer Møller2,3, Jordi Sanchez Dahl2, Rasmus Carter-Storch2, Nicolaj Lyhne Christensen2, Manan Pareek4, Jes Sanddal Lindholt5,6, Axel Cosmus Pyndt Diederichsen2,6.   

Abstract

To determine the presence and extent of aortic valve calcification (AVC) quantified by non-contrast cardiac computed tomography (NCCT), to determine the association between traditional cardiovascular risk factors and AVC score, and to evaluate the association between AVC and cardiac size and function assessed by echocardiography, in a general population aged 65-75 years. A random sample of 2060 individuals were invited to undergo NCCT through which their AVC score was assessed. Individuals with an AVC score ≥ 300 arbitrary units (AU) were invited for a transthoracic echocardiography together with age-matched controls. Descriptive statistics and multiple regression analyses were performed to identify risk factors associated with AVC and to describe associations between AVC score and echocardiographic findings. Of 2060 individuals invited 664 males and 636 females participated. Among those, 455 (68.5%) of males and 358 (56.3%) of females had AVC scores > 0 AU. The median AVC score was 6 AU (IQR 0-3064). Seventy-seven (11.6%) males and 20 (3.1%) females had an AVC score ≥ 300 AU. In a multiple regression analysis, age, sex, prior cardiovascular disease, smoking, and hypertension were associated with AVC score, while diabetes, hypercholesterolemia and kidney function were not. Individuals with AVC ≥ 300 AU had higher peak and mean aortic valve gradient, smaller indexed aortic valve area, greater left ventricular mass, and larger left atrial (LA) volume. In a random population sample of individuals aged 65-75 years, AVC was common and associated with most known cardiovascular risk factors. AVC ≥ 300 AU was associated with concentric remodeling and LA dilatation.

Entities:  

Keywords:  Aortic stenosis; Aortic valve calcification; Cardiovascular risk factors; Non-contrast cardiac CT; Transthoracic echocardiography

Mesh:

Year:  2020        PMID: 32915345     DOI: 10.1007/s10554-020-02012-2

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  38 in total

1.  Effect of bisphosphonates on the progression of degenerative aortic stenosis.

Authors:  Antony Leslie Innasimuthu; William E Katz
Journal:  Echocardiography       Date:  2011-01       Impact factor: 1.724

Review 2.  Lipid lowering on progression of mild to moderate aortic stenosis: meta-analysis of the randomized placebo-controlled clinical trials on 2344 patients.

Authors:  Koon K Teo; Daniel J Corsi; James W Tam; Jean G Dumesnil; Kwan L Chan
Journal:  Can J Cardiol       Date:  2011-07-13       Impact factor: 5.223

3.  Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly.

Authors:  C M Otto; B K Lind; D W Kitzman; B J Gersh; D S Siscovick
Journal:  N Engl J Med       Date:  1999-07-15       Impact factor: 91.245

4.  Angiotensin-converting enzyme inhibitors and change in aortic valve calcium.

Authors:  Kevin D O'Brien; Jeffrey L Probstfield; Michael T Caulfield; Khurram Nasir; Junichiro Takasu; David M Shavelle; Audrey H Wu; Xue-Qiao Zhao; Matthew J Budoff
Journal:  Arch Intern Med       Date:  2005-04-25

5.  A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.

Authors:  S Joanna Cowell; David E Newby; Robin J Prescott; Peter Bloomfield; John Reid; David B Northridge; Nicholas A Boon
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

Review 6.  Aortic stenosis.

Authors:  Blase A Carabello; Walter J Paulus
Journal:  Lancet       Date:  2009-02-21       Impact factor: 79.321

7.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

Authors:  Anne B Rossebø; Terje R Pedersen; Kurt Boman; Philippe Brudi; John B Chambers; Kenneth Egstrup; Eva Gerdts; Christa Gohlke-Bärwolf; Ingar Holme; Y Antero Kesäniemi; William Malbecq; Christoph A Nienaber; Simon Ray; Terje Skjaerpe; Kristian Wachtell; Ronnie Willenheimer
Journal:  N Engl J Med       Date:  2008-09-02       Impact factor: 91.245

8.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.

Authors:  Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

9.  Mortality while waiting for aortic valve replacement.

Authors:  S Chris Malaisrie; Eileen McDonald; Jane Kruse; Zhi Li; Edwin C McGee; Travis O Abicht; Hyde Russell; Patrick M McCarthy; Adin-Cristian Andrei
Journal:  Ann Thorac Surg       Date:  2014-09-18       Impact factor: 4.330

10.  Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis.

Authors:  Calvin W L Chin; Russell J Everett; Jacek Kwiecinski; Alex T Vesey; Emily Yeung; Gavin Esson; William Jenkins; Maria Koo; Saeed Mirsadraee; Audrey C White; Alan G Japp; Sanjay K Prasad; Scott Semple; David E Newby; Marc R Dweck
Journal:  JACC Cardiovasc Imaging       Date:  2016-12-21
View more
  2 in total

1.  Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial.

Authors:  Axel C P Diederichsen; Jes S Lindholt; Sören Möller; Kristian A Øvrehus; Søren Auscher; Jess Lambrechtsen; Susanne E Hosbond; Dilek H Alan; Grazina Urbonaviciene; Søren W Becker; Maise H Fredgart; Selma Hasific; Lars Folkestad; Oke Gerke; Lars Melholt Rasmussen; Jacob E Møller; Hans Mickley; Jordi S Dahl
Journal:  Circulation       Date:  2022-04-25       Impact factor: 39.918

2.  Aortic Valve Calcification Score in Patients with Arterial Hypertension Environmentally Exposed to Tobacco Smoke.

Authors:  Paweł Gać; Adrian Martuszewski; Patrycja Paluszkiewicz; Małgorzata Poręba; Grzegorz Mazur; Rafał Poręba
Journal:  Cardiovasc Toxicol       Date:  2021-07-26       Impact factor: 3.231

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.